PROTHENA CORP PUBLIC LTD CO
PRTA · XNASCIK 1559053fmd_1VF7AKM0MFAC91KAKYP4YRAXPQManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 28 | 1 | 1 | 1 | 201 | 54 | 91 | 135 | 10 |
| Net interest income | 1 | (0) | 3 | 8 | 1 | 0 | 6 | 31 | 26 | 14 |
| Research and development | 120 | 135 | 101 | 51 | 75 | 82 | 136 | 221 | 223 | 135 |
| Total operating expenses | 161 | 183 | 160 | 87 | 114 | 129 | 185 | 282 | 290 | 224 |
| Operating income | (160) | (155) | (159) | (86) | (113) | 72 | (132) | (191) | (155) | (215) |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 1 | (2) | 3 | 8 | 1 | (0) | 6 | 31 | 26 | 14 |
| Income before taxes | (159) | (158) | (156) | (77) | (111) | 72 | (126) | (160) | (129) | (201) |
| Income tax expense | 1 | (4) | (0) | 0 | (0) | 5 | (9) | (13) | (7) | 43 |
| Net income from continuing operations | (160) | (153) | (156) | (78) | (111) | 67 | (117) | (147) | (122) | (244) |
| Net income | (160) | (153) | (156) | (78) | (111) | 67 | (117) | (147) | (122) | (244) |